GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (OTCPK:INNMF) » Definitions » E10

Amplia Therapeutics (Amplia Therapeutics) E10 : $-0.14 (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Amplia Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Amplia Therapeutics's adjusted earnings per share data for the fiscal year that ended in Mar. 2023 was $-0.021. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.14 for the trailing ten years ended in Mar. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-01), Amplia Therapeutics's current stock price is $ 0.0487. Amplia Therapeutics's E10 for the fiscal year that ended in Mar. 2023 was $-0.14. Amplia Therapeutics's Shiller PE Ratio of today is .


Amplia Therapeutics E10 Historical Data

The historical data trend for Amplia Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics E10 Chart

Amplia Therapeutics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -0.14

Amplia Therapeutics Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -0.14 -

Competitive Comparison of Amplia Therapeutics's E10

For the Biotechnology subindustry, Amplia Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amplia Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's Shiller PE Ratio falls into.



Amplia Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amplia Therapeutics's adjusted earnings per share data for the fiscal year that ended in Mar. 2023 was:

Adj_EPS=Earnings per Share (Diluted) /CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=-0.021/123.1484*123.1484
=-0.021

Current CPI (Mar. 2023) = 123.1484.

Amplia Therapeutics Annual Data

per_share_eps CPI Adj_EPS
201403 -0.304 97.887 -0.382
201503 -0.204 99.187 -0.253
201603 -0.178 100.488 -0.218
201703 -0.224 102.624 -0.269
201803 -0.131 104.574 -0.154
201903 -0.030 105.967 -0.035
202003 -0.025 108.289 -0.028
202103 -0.018 109.496 -0.020
202203 -0.018 115.069 -0.019
202303 -0.021 123.148 -0.021

Add all the adjusted EPS together and divide 10 will get our e10.


Amplia Therapeutics  (OTCPK:INNMF) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Amplia Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Amplia Therapeutics (Amplia Therapeutics) Business Description

Traded in Other Exchanges
Address
350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (Amplia Therapeutics) Headlines